1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow SCD411 0.05mL (2mg): new trials by email Literature Review of SCD411 0.05mL (2mg) trials Research Report on SCD411 0.05mL (2mg)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy SCD411 0.05mL (2mg) - Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion | Phase 2 | Completed | Sam Chun Dang Pharm. Co. Ltd. | 33 | 2026-05-13 | 2026-06-08 |
Diabetic Retinopathy (1) · Macular Degeneration (1) · Retinal Vein Occlusion (1)
Sam Chun Dang Pharm. Co. Ltd. (1)
United States (1)
Byung Jhip Ha (1)